Toxicity quantitative structure--activity relationships of colchicines

Area of Science:

• Medicinal Chemistry
• Quantitative Structure-Activity Relationship (QSAR) Studies
• Drug Development

Background:

• Colchicines are a class of compounds with antitumor activity.
• Understanding the relationship between chemical structure, potency, and toxicity is crucial for drug development.
• Existing data on colchicines' antitumor effects can be leveraged to predict toxicity.

Purpose of the Study:

• To develop a method for extracting LD50 (Lethal Dose, 50%) values from existing antitumor test data for colchicines.
• To establish a quantitative structure-activity relationship (QSAR) for the toxicity of 7- and 10-substituted colchicines.
• To compare the toxicity QSAR with previously established potency QSAR and explore alternative structural modifications.

Main Methods:

• Extraction of LD50 values from antitumor experimental data.
• Development of a QSAR model correlating chemical structure with toxicity for specific colchinine substitutions.
• Comparative analysis of QSAR models for potency and toxicity.
• Evaluation of structure-toxicity relationships for ring A and 4-substituted colchicines.

Main Results:

• A QSAR equation for 7- and 10-substituted colchicines' toxicity was derived, closely mirroring the potency correlation.
• This suggests that reducing toxicity in these compounds may concurrently reduce their efficacy.
• Colchicines with modifications on ring A did not follow the established potency and toxicity correlations.
• 4-Substituted colchicines demonstrated potential for reduced toxicity, increased ILS (Increasable Lethal Dose), and a wider therapeutic index.

Conclusions:

• Attempts to decrease toxicity of 7- and 10-substituted colchicines are likely to impact potency negatively.
• Ring A modifications represent a deviation from predictable structure-activity and structure-toxicity relationships.
• 4-Substituted colchicines offer a promising avenue for developing less toxic and potentially more effective antitumor agents.